A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor

Kathleen A. Fitzgerald; Meenakshi Malhotra; Matt Gooding; Florence Sallas; James C. Evans; Raphael Darcy; Caitriona O'Driscoll

A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor

Kathleen A. Fitzgerald
, Meenakshi Malhotra
, Matt Gooding
, Florence Sallas
, James C. Evans
, Raphael Darcy
, Caitriona O'Driscoll

School of Pharmacy

University College Dublin
Centre for Synthesis and Chemical Biology

Research output: Contribution to journal › Article › peer-review

Original language	English (Ireland)
Pages (from-to)	131-145
Journal	International Journal of Pharmaceutics
Volume	499
Issue number	1-2
Publication status	Published - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{8e4972e1b9c647b79a47f75499767e76,

title = "A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor",

author = "Fitzgerald, \{Kathleen A.\} and Meenakshi Malhotra and Matt Gooding and Florence Sallas and Evans, \{James C.\} and Raphael Darcy and Caitriona O'Driscoll",

year = "2016",

language = "English (Ireland)",

volume = "499",

pages = "131--145",

journal = "International Journal of Pharmaceutics",

issn = "0378-5173",

publisher = "Elsevier B.V.",

number = "1-2",

}

TY - JOUR

T1 - A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor

AU - Fitzgerald, Kathleen A.

AU - Malhotra, Meenakshi

AU - Gooding, Matt

AU - Sallas, Florence

AU - Evans, James C.

AU - Darcy, Raphael

AU - O'Driscoll, Caitriona

PY - 2016

Y1 - 2016

M3 - Article

SN - 0378-5173

VL - 499

SP - 131

EP - 145

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

IS - 1-2

ER -